Kathleen Elias

Kathleen has over 25 years of drug development experience working in biotech and pharmaceutical settings. Dr. Elias previously worked at Takeda, as a Director of Preclinical Research, and led efforts to develop small molecule, antibody, and ADC oncology therapeutics, as well as immunological and metabolic therapies.

Prior to that, she worked at Cytokinetics to establish and lead the cell biology and pharmacology efforts to identify and develop a myosin activator therapeutic for heart failure currently in Phase 3 with Amgen. At Genentech, she was a scientist working in endocrine and cardiac therapeutic areas. During her career, Dr. Elias has contributed to multiple agents that have advanced to clinical development and is an author of numerous publications and patents. She received a Ph.D. from the University of Nebraska Medical Center and was a post-doctoral fellow at the University of California, San Francisco.